Analyst consensus rating
UroGen Pharma Analyst Rating: Strong Buy
Direct answer
UroGen Pharma's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $60.00.
Forecast evidence checked September 12, 2026.
Get free UroGen Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $42.31
- Average price target
- $60.00
- High price target
- $75.00
- Low price target
- $48.00
- Low target gap
- +13.4%
- Target upside
- +41.8%
- High target gap
- +77.3%
- Target range width
- 63.8%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- September 12, 2026
- Valid through
- September 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for UroGen Pharma?
UroGen Pharma has a verified Strong Buy consensus. The same dataset has an average price target of $60.00.
How far are UroGen Pharma's low and high targets from the recorded price?
The low target implies +13.4%, while the high target implies +77.3%.
How many analysts are included in UroGen Pharma's consensus?
The verified consensus includes 8 analysts.
How is UroGen Pharma's target upside or downside calculated?
The average target of $60.00 is divided by the recorded price of $42.31, then one is subtracted to produce +41.8%. This does not guarantee a future return.
When was UroGen Pharma's analyst forecast verified?
The data was verified on 2026-09-12. The dataset is valid through 2026-09-19.